1,146 results match your criteria: "HCL Cancer Institute & Lyon 1 University[Affiliation]"

Dupilumab in atopic-dermatitis-like eczema associated with inborn errors of immunity: A nationwide study.

J Am Acad Dermatol

January 2025

Department of Dermatology, Reference Center for Genodermatoses (MAGEC), Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Cité University, Paris, France; Imagine Institute, INSERM UMR1163, Paris Cité University, Paris, France. Electronic address:

View Article and Find Full Text PDF
Article Synopsis
  • A phase 3 trial found that 12 months of adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with high-risk stage III melanoma compared to placebo, with longer follow-up data available.
  • With a median follow-up of 6.9 years, the pembrolizumab group showed a 50% RFS at 7 years versus 36% for the placebo group, and a 54% DMFS compared to 42% in the placebo group.
  • The results indicated consistent positive outcomes across various melanoma subtypes, confirming the long-term benefits of pembrolizumab in improving survival metrics in these patients.
View Article and Find Full Text PDF

[Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations].

Bull Cancer

September 2024

IUCT Oncopôle Toulouse, service d'urologie, Toulouse, France; Clinique La Croix du Sud, UROSUD, Toulouse, France.

Castration-resistant metastatic prostate cancer remains lethal and a therapeutic challenge. Current strategies are geared towards the personalization of treatments based on the identification of relevant molecular targets, including genomic alterations involved in tumoral processes. Among these novel targeted therapies, poly-ADP-ribose polymerase inhibitors (PARPi), by blocking the action of enzymes involved in deoxyribonucleic acid (DNA) repair, induce the destruction of cells carrying defects in homologous recombination repair, often associated with alterations in genes involved in this mechanism.

View Article and Find Full Text PDF

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?

ESMO Open

September 2024

Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address:

Article Synopsis
  • Elacestrant, an oral selective estrogen receptor degrader (SERD), has been shown to be superior to standard therapies for patients with ESR1-mutant tumors, based on the EMERALD trial results, and is now included in clinical guidelines.
  • Access to elacestrant in Europe is subject to local health authority decisions, but it offers a significant benefit to certain patients by avoiding more aggressive treatments and improving their quality of life.
View Article and Find Full Text PDF

Utilizing medicinal plants and other natural resources to prevent different types of human cancers is the prime focus of attention. Cervical cancer in women ranks as the fourth most common type of malignancy. The current study used gas chromatography-mass spectrometry (GC-MS) to identify the active phytochemical constituents from Caladium lindenii leaf extracts using ethanol (ECL) and n-hexane (HCL) solvents.

View Article and Find Full Text PDF

Steroidal 21-imidazolium salt derivatives: Synthesis and anticancer activity.

Steroids

October 2024

Laboratory of Organic Synthesis, Institute of Chemistry, Moldova State University, Academiei Str., 3, MD-2028 Chișinău, Moldova. Electronic address:

Nitrogen-containing steroids are known as prostate cancer therapeutics. In this work, a series of pregnane derivatives bearing an imidazolium moiety were synthesized using Δ-20-ketones as starting material. An improved approach for the construction of the 20-keto-21-heterocycle-substituted fragment involved the rearrangement of 16,17-epoxides with HCl, followed by reaction of the formed α-chloroketone with 1-substituted imidazoles.

View Article and Find Full Text PDF

This study focuses on the synthesis and structural characterization of new compounds that integrate thiazolidine-2,4-dione, acridine moiety, and an acetamide linker, aiming to leverage the synergistic effects of these pharmacophores for enhanced therapeutic potential. The newly designed molecules were efficiently synthesized through a multi-step process and subsequently transformed into their hydrochloride salts. Comprehensive spectroscopic techniques, including nuclear magnetic resonance (NMR), high-resolution mass spectrometry (HRMS), infrared (IR) spectroscopy, and elemental analysis, were employed to determine the molecular structures of the synthesized compounds.

View Article and Find Full Text PDF
Article Synopsis
  • * Among the leukemias, acute myeloid leukemia (AML) is highly aggressive with poor survival rates, especially in patients with specific gene mutations, while hairy cell leukemia (HCL) remains rare and untreated with approved drugs.
  • * New epigenetic therapies, particularly histone deacetylase (HDAC) inhibitors, show promise in targeting blood cancers, with new hydroxamic acid derivatives demonstrating effectiveness in inducing cell death and improving outcomes in models of AML and other blood cancers.
View Article and Find Full Text PDF

Background: Medicinal plant-mediated combinational therapies have gained importance globally due to minimal side effects and enhanced treatment outcomes compared to single-drug modalities. We aimed to analyze the cytotoxic potential of each conventional treatment i.e.

View Article and Find Full Text PDF

Fisetin ameliorates polycystic ovary syndrome in rats via a mechanistic modulation of AMP-activated protein kinase and SIRT1 molecular pathway.

Naunyn Schmiedebergs Arch Pharmacol

December 2024

University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, 140413, Punjab, India.

Fisetin, a polyphenolic flavonoid, exhibits numerous pharmacological activities against metabolic syndromes. The present research aims to explore the therapeutic efficacy of fisetin in experimental polycystic ovary syndrome (PCOS). Female Sprague-Dawley rats were administered mifepristone (20 mg/kg/day) to induce PCOS.

View Article and Find Full Text PDF
Article Synopsis
  • Non-obstructive azoospermia (NOA) from primary spermatogenic failure is a severe male infertility issue with limited treatment options, and genetic testing can help predict outcomes for procedures like testicular sperm extraction (TESE).
  • A study using whole-genome sequencing on an Iranian family revealed a harmful variant in the TDRKH gene, which is crucial for male fertility; its absence leads to sperm production failures similar to findings in Tdrkh knockout mice.
  • This research reinforces the importance of the piRNA pathway in spermatogenesis and indicates that men with TDRKH variants have a high likelihood of complete spermatogenic arrest, similar to previously studied North African cases.
View Article and Find Full Text PDF
Article Synopsis
  • Hairy-cell leukemia (HCL) is a rare blood cancer that has improved prognosis due to treatments like purine nucleoside analogs, but some patients experience relapses and chemotherapy resistance.
  • Recent advances in understanding HCL's genetic and cellular mechanisms have led to the development of targeted therapies, including BRAF and MEK inhibitors.
  • Updated guidelines emphasize the importance of BRAF mutation for diagnosis, the relevance of certain immunoglobulin mutations for prognosis, and recommend strategies for managing both HCL and similar disorders.
View Article and Find Full Text PDF

Indoor formaldehyde pollution can cause inestimable harm to human health and even cancers, thus studies on the removal of formaldehyde attract extensive attentions. In this paper, an environmentally friendly and low-cost biomass material, sodium alginate (SA) was utilized to prepare pyrene functionalized amido-amine-alginic acid (AmAA-Py) by acidification and two-step amidation, which is subsequently self-assembled on reduced graphene oxide (rGO) by π-π stacking interaction, and the final composites were acidified to afford a highly porous composite material for chemical removal of formaldehyde. The formaldehyde chemical removal performance of composite is evaluated at different conditions and find that 1.

View Article and Find Full Text PDF

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.

Br J Cancer

September 2024

Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France.

Background: Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody-drug conjugates (ADCs): Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), despite a similar payload. However, the effectiveness of one after another is unknown.

Methods: ADC-Low is a multicentre, retrospective study evaluating the efficacy of SG and T-DXd, one after another, with or without intermediary lines of chemotherapy, in patients with HER2-low MBC.

View Article and Find Full Text PDF

Ferroptosis inhibitor improves outcome after early and delayed treatment in mild spinal cord injury.

Acta Neuropathol

June 2024

Centre for Research in Neuroscience, The BRAiN Program, The Research Institute of the McGill University Health Centre, Livingston Hall, Room L7-210, 1650 Cedar Ave., Montreal, QC, H3G 1A4, Canada.

We show that redox active iron can induce a regulated form of non-apoptotic cell death and tissue damage called ferroptosis that can contribute to secondary damage and functional loss in the acute and chronic periods after spinal cord injury (SCI) in young, adult, female mice. Phagocytosis of red blood cells at sites of hemorrhage is the main source of iron derived from hemoglobin after SCI. Expression of hemeoxygenase-1 that induces release of iron from heme, is increased in spinal cord macrophages 7 days after injury.

View Article and Find Full Text PDF

Measurable residual disease (MRD) surveillance in acute myeloid leukemia (AML) may identify patients destined for relapse and thus provide the option of pre-emptive therapy to improve their outcome. Whilst flow cytometric MRD (Flow-MRD) can be applied to high-risk AML/ myelodysplasia patients, its diagnostic performance for detecting impending relapse is unknown. We evaluated this in a cohort comprising 136 true positives (bone marrows preceding relapse by a median of 2.

View Article and Find Full Text PDF

Methotrexate is a potent anticancer drug whose strong efflux is facilitated by the brain's efflux transporter. As an efflux transporter blocker, albumin increased the drug's concentration in the brain. Methotrexate-loaded nanoparticles were produced by evaporating the emulsification fluid.

View Article and Find Full Text PDF

KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.

Biomark Med

August 2024

EA UCBL/HCL 3738, Centre pour l'lnnovation en Cancérologie de Lyon (CICLY), Faculty of Medicine Lyon-Sud, Claude Bernard University Lyon 1, Oullins-Pierre-Bénite, 69921, France.

View Article and Find Full Text PDF

Background: Visualization of cancer during breast conserving surgery (BCS) remains challenging; the BCS reoperation rate is reported to be 20-70% of patients. An urgent clinical need exists for real-time intraoperative visualization of breast carcinomas during BCS. We previously demonstrated the ability of a prototype imaging device to identify breast carcinoma in excised surgical specimens following 5-aminolevulinic acid (5-ALA) administration.

View Article and Find Full Text PDF

Purpose: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are expected to be synergistic with intraperitoneal (IP) immunotherapy by increasing tumor antigen expression and mutational load. We assessed the feasibility and safety of IP nivolumab following complete CRS and HIPEC in pretreated patients with recurrent ovarian cancer (ClinicalTrials.gov identifier: NCT03959761).

View Article and Find Full Text PDF
Article Synopsis
  • A study aimed to identify rare oncogenic driver events in hematologic malignancies by analyzing a large dataset of whole genome and RNA sequencing from 3,760 patients across 24 disease types.
  • The research utilized advanced techniques like the DROP pipeline and machine learning to pinpoint expression and splicing outliers, discovering a median of seven expression outlier genes and significant enrichment for known driver genes in their findings.
  • Notably, the study identified LRP1B, a previously underexplored gene, as a potential new marker for hairy cell leukemia variant (HCL-V), indicating its significance in understanding this specific cancer type.
View Article and Find Full Text PDF

Hairy cell leukemia (HCL) and HCL-like disorders have to be distinguished because of their different biology and treatment response. Thus, we conducted a retrospective study on patients with HCL and hairy cell leukemia variant (HCLv) to assess diagnostic algorithms and treatment outcomes in a real-world setting. We analyzed 225 HCL and 26 HCLv patients with median follow-up of 67.

View Article and Find Full Text PDF